Home -
Products -
GPCR/G Protein -
CGRP Receptor -
Calcitonin(salmon) Acetate(47931-85-1(free base))
Calcitonin(salmon) Acetate(47931-85-1(free base))
CAS No. ——
Calcitonin(salmon) Acetate(47931-85-1(free base))( Salmon calcitonin )
Catalog No. M22788 CAS No. ——
Calcitonin(salmon) Acetate, a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.Oral Calcitonin salmon treatment dose-dependently attenuates fasting and non-fasted hyperglycaemia during the intervention period.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 223 | In Stock |
|
| 10MG | 373 | In Stock |
|
| 25MG | 455 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCalcitonin(salmon) Acetate(47931-85-1(free base))
-
NoteResearch use only, not for human use.
-
Brief DescriptionCalcitonin(salmon) Acetate, a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.Oral Calcitonin salmon treatment dose-dependently attenuates fasting and non-fasted hyperglycaemia during the intervention period.
-
DescriptionCalcitonin(salmon) Acetate, a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.Oral Calcitonin salmon treatment dose-dependently attenuates fasting and non-fasted hyperglycaemia during the intervention period. At the end of the study period, oral Calcitonin salmon treatment by dose decreases diabetic hyperglycaemia by ~9 mM and reduces HbA1c levels by 1.7%. Furthermore, a pronounced reduction in glucose excursions is dose-dependently observed for oral Calcitonin salmon treatment during oral glucose tolerance test. In addition, oral Calcitonin salmon treatment sustains hyperinsulinaemia and attenuates hyperglucagonaemia and hypersecretion of total glucagon-like peptide-1 predominantly in the basal state. Lastly, oral Calcitonin salmon treatment dose-dependently improves pancreatic beta-cell function and beta-cell area at study end.
-
In Vitro——
-
In Vivo——
-
SynonymsSalmon calcitonin
-
PathwayGPCR/G Protein
-
TargetCGRP Receptor
-
Recptorcalcitonin receptor|amylin
-
Research AreaOthers
-
IndicationForearm Fracture
Chemical Information
-
CAS Number——
-
Formula Weight3431.85
-
Molecular FormulaC145H240N44O48S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNC(=O)CC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc2cncn2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N4CCC[C@H]4C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O.CC(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Feigh M, et al. Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats. Br J Pharmacol. 2012 Sep;167(1):151-63.
molnova catalog
related products
-
MK-8825
MK-8825 is a highly potent, selective, orally bioavailable CGRP receptor antagonist with Ki of 17 nM for rat CGRP.
-
Ubrogepant
Ubrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine.
-
MK-3207
A highly potent, selective CGRP receptor antagonist with Ki of 21 pM in in vitro binding assay and IC50 of 0.12 nM in cell-based functional assay.
Cart
sales@molnova.com